LRRC20

Across TCGA pan-cancer cohorts, LRRC20 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of LRRC20’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where LRRC20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LRRC20 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

KIRP, LUAD, and COAD are the cancer types where LRRC20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRRC20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Male	II,III,IV	+1.824	<.001	11	view →
LUAD	Male	III,IV	+1.536	<.001	11	view →
COAD	Female	All	+1.383	<.001	11	view →
KIRC	All	IV	+0.693	<.001	11	view →
LIHC	All	III,IV	+1.323	<.001	9	view →
HNSC	Male	IV	−1.593	<.001	8	view →
BRCA	All	II,III,IV	+0.532	<.001	6	view →
THCA	All	II,III,IV	+0.216	.027	4	view →
CHOL	All	All	+0.928	<.001	3	view →
UCEC	All	III,IV	+0.944	.043	2	view →
STAD	All	II,III,IV	+0.704	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

LRRC20–KIRP

Open the KIRP breakdown →